RecruitingPhase 4NCT07538570

Evaluation of Pain Treatment After Total Knee Arthroplasty

A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty

Sponsor

Vertex Pharmaceuticals Incorporated

Enrollment

60 participants

Start Date

Apr 24, 2026

Study Type

INTERVENTIONAL

Conditions

Pain

Summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria2

Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
Scheduled to undergo an elective primary unilateral TKA surgery

Exclusion Criteria1

\- History of previous TKA surgery on incident side

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSuzetrigine

Tablets for oral administration.

DRUGPlacebo

Placebo matched to SUZ for oral administration

Locations(2)

Legent Orthopedic and Spine Hospital

Bellaire, Texas, United States

Memorial Hermann Village Office

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07538570

Related Trials

Anatomical Axis on X-Ray and Its Relationship With Pain and Kinesiophobia in Knee Osteoarthritis

NCT071685901 location